LEXINGTON, Mass.--(BUSINESS WIRE)--N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced that it has signed a business partner agreement with Affymetrix, a leading provider of DNA microarrays. Under this agreement, N-of-One will provide copy number variation (CNV) analysis interpretation for Affymetrix OncoScan assay customers. Financial terms of the agreement are not disclosed.
Affymetrix OncoScan assay provides a genome-wide copy number profile from a solid tumor sample. The analysis of copy number aberrations has been shown to inform therapeutic strategies in oncology. Combining whole-genome copy number analysis, LOH, and somatic mutation data enables a deeper understanding of each patient’s cancer.
N-of-One is working closely with Affymetrix to ensure that data from OncoScan assay combined with N-of-One interpretation optimize for clinicians the value of tumor profiling based on CNV analysis. N-of-One delivers highly scalable, cost-effective interpretation that is patient specific and can be configured to the needs of each organization. The combination will deliver the understanding of CNV analysis that is required by clinicians to assist in identifying targeted therapeutic strategies in clinical research and clinical trials.
“Affymetrix selected N-of-One because of their extensive experience delivering high quality clinical interpretation, which provides valuable insights to clinicians,” said Kim Caple, Affymetrix Senior Vice President and General Manager, Clinical Business. “The combination of OncoScan assay and N-of-One interpretation will provide highly valuable intelligence to aid clinicians as they decide individual treatment options for their clinical research.”
“N-of-One is very pleased to team with Affymetrix”, said Chris Cournoyer, CEO of N-of-One. “We are focused on partnering with Affymetrix to meet the growing demand for OncoScan assay by delivering high quality, cost-effective and scalable interpretation that meets their business objectives.”
Affymetrix technologies enable multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level, facilitating the rapid translation of bench-top research into clinical and routine use for human health and wellness. The Company provides leadership and support, partnering with customers in pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and non-profit research institutes in their quest to use biology for a better world. More than 2,300 microarray systems have been shipped around the world and more than 94,500 peer-reviewed papers have been published citing Affymetrix technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, Ohio, San Diego, Vienna, and Singapore. The Company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit www.affymetrix.com.
OncoScan is for: Research Use Only. Not for use in diagnostic procedures.
N-of-One, a leader in enabling precision medicine for oncology, leverages its world-class team of experts coupled with a highly proprietary platform that allows us to provide clinical solutions and services , such as molecular interpretation, to clinicians at the point of care. N-of-One’s team of experts has interpreted thousands of samples for oncologists and patients worldwide, through partnerships with leading diagnostic companies, hospital systems, directly to oncologists and through employee access benefit programs. N-of-One does not provide medical advice or promote any product or service. For more information, please visit www.n-of-one.com or call 617-202-9808.